Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines

Citations Over TimeTop 10% of 2016 papers

Abstract

Although glycoconjugate vaccines are generally very efficacious, there is still a need to improve their efficacy, especially in eliciting a strong primary antibody response. We have recently described a new type of vaccine adjuvant based on a TLR7 agonist adsorbed to alum (Alum-TLR7), which is highly efficacious at enhancing immunogenicity of protein based vaccines. Since no adjuvant has been shown to potentiate the immune response to glycoconjugate vaccines in humans, we investigated if Alum-TLR7 is able to improve immunogenicity of this class of vaccines. We found that in a mouse model Alum-TLR7 greatly improved potency of a CRM197-MenC vaccine increasing anti-MenC antibody titers and serum bactericidal activity (SBA) against MenC compared to alum adjuvanted vaccine, especially with a low dose of antigen and already after a single immunization. Alum-TLR7 also drives antibody response towards Th1 isotypes. This adjuvant was also able to increase immunogenicity of all polysaccharides of a multicomponent glycoconjugate vaccine CRM197-MenACWY. Furthermore, we found that Alum-TLR7 increases anti-polysaccharide immune response even in the presence of a prior immune response against the carrier protein. Finally, we demonstrate that Alum-TLR7 adjuvant effect requires a functional TLR7. Taken together, our data support the use of Alum-TLR7 as adjuvant for glycoconjugate vaccines.

Related Papers

• → Alum adjuvant: some of the tricks of the oldest adjuvant(2011)317 cited
• → Immunogenicity and Protective Efficacy in Mice and Hamsters of a β-Propiolactone Inactivated Whole Virus SARS-CoV Vaccine(2010)72 cited
• → Deciphering the structure–immunogenicity relationship of anti-Candidaglycoconjugate vaccines(2014)61 cited
• → The ISCOM: an immunostimulating complex(1987)130 cited
• DDA is More Efficacious Than MPL as Adjuvants That Enhanced Immunogenicity and Protection of Combined DNA Vaccine Against Mycobacterium tuberculosisa(2005)